Ozempic treats alcohol abuse disorder? (August SPBC replay) | Howtown on Patreon
This is a Patreon-locked replay from the Howtown channel's August SPBC show, asking whether Ozempic might treat alcohol abuse disorder. Most of the post is behind a paywall, so the visible text only shows the teaser question and some unrelated community notes.
- The episode's core question is whether semaglutide (Ozempic) can treat alcohol abuse disorder.
- The visible portion is mostly paywall text, so the actual evidence and claims aren't available here.
- A related preview cites the oft-repeated "sperm counts fell 50% in 50 years" figure, which the post treats as a media-amplified stat.
The page you've given me is mostly a paywall wrapper for a Patreon post from the Howtown channel, titled "Ozempic treats alcohol abuse disorder? (August SPBC replay)." Almost all of the body is locked behind a membership, so what's actually readable is navigation, a teaser, and some boilerplate. The headline question is the substance: whether semaglutide, the drug sold as Ozempic, might help with alcohol use disorder. That is an active research area, with early trials and animal studies suggesting GLP-1 drugs reduce drinking, and the post appears to be a replay of a livestream examining that claim. I can't tell from what's visible whether the creator endorses the idea, how strong the evidence they cite is, or what conclusions they reach.
The visible excerpts point to a few other threads. One is a discussion of a widely repeated statistic that sperm counts have fallen 50% over 50 years, which the excerpt notes came from pooled studies showing a 42% drop since 1938 and was then amplified by media until the rounder figure became standard. That reads like a warning about how data gets distorted as it travels, and it's the one piece of the page with a concrete, checkable claim. The other is a community-focused note about a "rapidly changing world" and a monthly members' call with Howtown's mayors and council members, scheduled for Friday at 1pm Eastern.
If you want the actual argument and the sources behind it, you'd need to join the membership or find the same material elsewhere. For a read-it-later save, I'd tag this as a paywalled video replay on a medical question, and flag the sperm count passage as the part most worth checking against the original studies.
Ask about this article
Is there evidence GLP-1 drugs reduce drinking in humans?
Yes, there's human evidence, though it's mostly small trials and observational data. The strongest randomized evidence is recent, and it's mixed.
**Randomized trials**
- **Low-dose semaglutide, non-treatment-seeking adults (phase 2, 2025):** Forty-eight participants (34 [71%] female; mean [SD] age, 39.9 [10.6] years) were randomized. The results were partial. Over 9 weeks of treatment, semaglutide led to reductions in some but not all measures of weekly consumption, significantly reduced weekly alcohol craving relative to placebo. In the lab, low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration procedure.
- **Semaglutide in treatment-seeking adults with AUD and obesity (Lancet, 2026):** This is the strongest result so far. This randomised, double-blind, placebo-controlled clinical trial shows, for the first time, to our knowledge, that the GLP-1 receptor agonist semaglutide at 2·4 mg once-weekly reduces alcohol consumption in treatment-seeking patients with alcohol use disorder and comorbid obesity (BMI ≥30 kg/m^2). Semaglutide was associated with a reduction in heavy drinking days (–41·1 percentage points from baseline, 95% CI –48·7 to –33·5) compared with placebo (–26·4, –34·1 to –18·6). Earlier, only one randomised controlled trial (RCT) of GLP-1 receptor agonists in treatment-seeking patients with alcohol use disorder showed no overall effect on heavy drinking days.
- **Oral semaglutide (American Journal of Psychiatry, 2026):** Results were more mixed. In the last 4 weeks of treatment, semaglutide, relative to placebo, significantly reduced heavy drinking days, but it did not significantly reduce cue-elicited craving in the lab, though other craving measures improved.
**Observational data**
- A VA cohort study (JCI, 2025) compared changes in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores between propensity-score–matched GLP-1RA recipients, DPP-4I recipients, and unexposed comparators.
- A large All of Us analysis found statistically significant but modestly lower AUDIT-C scores on average among current users. Its authors say GLP-1RAs may reduce alcohol consumption by decreasing use frequency. The effect is small, and the study can't establish cause.
- A meta-analysis of RCTs and observational studies (2025) concluded that GLP-1 RAs, particularly Semaglutide and liraglutide, reduce alcohol use as measured by AUDIT scores. Pooling is useful here, but it mixes weak and strong designs.
**Bottom line**
Human evidence now supports a real effect, at least for semaglutide in people with obesity who are trying to cut down. The trials are still small, the first one was null overall, and the 2026 Lancet trial is one study. Researchers say larger trials are still needed. The Patreon post is a replay of a podcast, so I couldn't check its specific claims, but the research above is the relevant evidence.